Immunologic Factor
eculizumab Audio
[ ek-yoo-lih-zoo-mab ]
Brand Names:
Soliris
May Treat:
Atypical Hemolytic Uremic Syndrome; Hemoglobinuria, Paroxysmal
More Information:
ChemID; DrugBank; DailyMed; PDR
Definitions related to eculizumab:
  • A humanized monoclonal antibody directed against terminal complement protein C5. Eculizumab binds to terminal complement protein C5, thereby blocking C5 cleavage into pro-inflammatory components and blocking the complement-mediated destruction of paroxysmal nocturnal hemoglobinuria (PNH) red blood cells. (NCI05)
    NCI
    U.S. National Cancer Institute, 2021
  • A monoclonal antibody used to prevent red blood cells from being destroyed in patients with paroxysmal nocturnal hemoglobinuria (PNH), a red blood cell disorder. Monoclonal antibodies are made in the laboratory and can locate and bind to substances in the body. Eculizumab blocks a protein in the blood that causes the breakdown of red blood cells.
    NCI Dictionary of Cancer Terms
    U.S. National Cancer Institute, 2021
Try this search on: Farlex, Merriam-Webster, Oxford Dictionary, or Wordnik

This content should not be used in place of medically-reviewed decision support reference material or professional medical advice. Some terms may have alternate or updated definitions not reflected in this set. The definitions on this page should not be considered complete or up to date.